Levation Pharma Business
Product stage
Clinical Trial
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCosmetics
Core Technology
—
Tags (5)
drug-discoveryeye-diseasespharmaceuticalstopical-treatmentophthalmology
Levation Pharma Financials
Undisclosed
Capital raised
Cumulative Funding Raised Over Time ($)
Private Equity Funding
Peregrine Ventures (Lead)
,
Pontifax
Levation Pharma Lifecycle
Cumulative Funding Raised Over Time
All Events
Peregrine Ventures (Lead)
,
Pontifax
Levation Pharma News
1 article
Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis
Levation Pharma, a pharmaceutical company specializing in ophthalmology and aesthetic therapeutics, has received FDA clearance to initiate a Phase I/II clinical trial for LEV102, a treatment for Acquired Blepharoptosis in adults. The condition, characterized by drooping of the upper eyelid, can impair vision and give an appearance of aging and tiredness. LEV102 is a proprietary aqueous gel that includes oxymetazoline as the active ingredient, intended to activate receptors on Mueller’s muscle in the upper lid. The clinical trial aims to determine preliminary safety and efficacy signals for LEV102. Levation Pharma is an Israeli-American company based in Los Angeles and is backed by venture firms Pontifax and Peregrine.
Investment
Levation Pharma Team
Houman David Hemmati MD, PhD
Co-Founder & Chief Scientific Officer
Founder
Employee Info
| Employees (range) | 1-10 |
| Exact count | 2 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.